

S/N 10/502,119

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	LAUTT ET AL.	Examiner:	PURNELL
Serial No.:	10/502,119	Group Art Unit:	1632
Filed:	JANUARY 12, 2005	Docket No.:	14430.6USWO
Title:	USE PHOSPHODIESTERASE ANTAGONISTS TO TREAT INSULIN RESISTANCE		

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. § 1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.


Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
612.332.5300

Date: July 13, 2007



Brian R. Dorn
Reg. No. 57,395
BDorn:jm



FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 14430.6USWO	Application Number: 10/502,119
	Applicant: Lautt	
	Filing Date: January 12, 2005	Group Art Unit: 1632

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2003/0114469	6-19-2003	Cohen			
	2003/0166662	9-4-2003	Fryburg et al.			
	2003/0181461	9-25-2003	Lautt			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Restriction Requirement dated September 9, 2005 in U.S. Appl. No. 10/350,070 (U.S. Pat. Appl. Pub. No. 2003/0181461)
		Correia et al., "Hepatic guanyl cyclase inhibition induced HISS-dependent insulin resistance," Proc. West. Pharmacol. Soc. 45: 57-58 (2002).
		Sadri et al., "Blockade of hepatic nitric oxide synthase causes insulin resistance," Am. J. Physiol. 277: G101-G108 (1998).
		Xie et al., "Insulin sensitivity tested with a modified euglycemic technique in cats and rats," J. Pharmacol. Toxicol. Methods 35: 77-82 (1996).

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	